Context Therapeutics Inc. (CNTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Context Therapeutics reported revenue of $0. Net income was -$36.1M, or -$0.38 per diluted share. Operating activities generated -$26.4M of cash, leaving -$26.4M of free cash flow. At fiscal year end, Context Therapeutics held $68.5M in total assets against $8.0M in total liabilities, including $66.0M of cash and equivalents.
Open the full interactive Context Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Context Therapeutics Key Stats
| Share Price | $0.28 |
|---|---|
| Market Cap | $26.2M |
| 52-Week Range | $0.28 – $3.36 |
| Shares Outstanding | 95.2 million (basic, 2026 Q2) |
Context Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$10.5M | -$15.4M | -$25.1M | -$29.9M | -$39.7M |
| Pre-Tax Income | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| Diluted EPS | -$3.69 | -$0.93 | -$1.50 | -$0.46 | -$0.38 |
Context Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$9.7M | -$13.0M | -$8.7M | -$14.6M |
| Diluted EPS | -$0.10 | -$0.14 | -$0.09 | -$0.15 |
Context Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $49.6M | $35.5M | $14.4M | $94.4M | $66.0M |
| Current Assets | $51.3M | $37.9M | $16.0M | $97.9M | $68.4M |
| Total Assets | $51.3M | $38.0M | $16.1M | $98.1M | $68.5M |
| Current Liabilities | $3.0M | $3.2M | $4.2M | $2.7M | $8.0M |
| Total Liabilities | $3.0M | $3.2M | $4.2M | $2.9M | $8.0M |
| Shareholders' Equity | $48.3M | $34.8M | $11.9M | $95.3M | $60.5M |
Context Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$8.8M | -$13.5M | -$21.0M | -$14.6M | -$26.4M |
| Cash From Investing | -$250,000 | -$536,836 | $0 | -$14.8M | -$2.0M |
| Cash From Financing | $58.4M | -$102,071 | $0 | $109.3M | -$15,268 |
| Free Cash Flow | — | -$13.6M | -$21.0M | -$14.6M | -$26.4M |
Figures from Context Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Context Therapeutics financials page for every line item.
Context Therapeutics Company Profile
| Ticker | CNTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Philadelphia, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001842952 |
Frequently Asked Questions
What was Context Therapeutics' revenue in fiscal 2025?
Context Therapeutics (CNTX) reported revenue of $0 for fiscal 2025.
What is Context Therapeutics' annual revenue history?
Context Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Context Therapeutics' net income in fiscal 2025?
Context Therapeutics reported net income of -$36.1M for fiscal 2025.
What was Context Therapeutics' earnings per share (EPS) in fiscal 2025?
Context Therapeutics' diluted EPS was -$0.38 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Context Therapeutics generate in fiscal 2025?
Context Therapeutics generated -$26.4M of free cash flow in fiscal 2025.
What was Context Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Context Therapeutics reported revenue of $0.
How many shares of Context Therapeutics are outstanding?
Context Therapeutics reported a weighted average of 95.2 million basic shares outstanding in 2026 Q2.
What is Context Therapeutics' market cap?
Based on its latest closing price, Context Therapeutics (CNTX) has a market capitalization of about $26.2M.
When does Context Therapeutics' fiscal year end?
Context Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Context Therapeutics headquartered?
Context Therapeutics lists its business address in Philadelphia, Pennsylvania in its SEC filings.